BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 30961617)

  • 41. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
    Chaturvedi A; Battmer K; Schaefer D; Ganser A; Eder M; Scherr M
    Oligonucleotides; 2007; 17(1):22-34. PubMed ID: 17461760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.
    Shinohara H; Kumazaki M; Minami Y; Ito Y; Sugito N; Kuranaga Y; Taniguchi K; Yamada N; Otsuki Y; Naoe T; Akao Y
    Cancer Lett; 2016 Feb; 371(1):1-11. PubMed ID: 26607903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells.
    Li L; Zhang R; Fang ZY; Chen JN; Zhu ZL
    J Int Med Res; 2009; 37(2):426-37. PubMed ID: 19383237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
    Yuanxin Y; Yanhong Z; Qin Z; Sishi T; Yang D; Yi Z; Minjin W; Juan Z; Xiaojun L; Lanlan W; Binwu Y
    Leuk Res; 2019 Apr; 79():6-16. PubMed ID: 30784762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
    Hjort EE; Huang W; Hu L; Eklund EA
    Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Sherr CJ
    Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
    Warsch W; Kollmann K; Eckelhart E; Fajmann S; Cerny-Reiterer S; Hölbl A; Gleixner KV; Dworzak M; Mayerhofer M; Hoermann G; Herrmann H; Sillaber C; Egger G; Valent P; Moriggl R; Sexl V
    Blood; 2011 Mar; 117(12):3409-20. PubMed ID: 21220747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
    Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
    Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
    Ishiura M; Kitai Y; Kashiwakura JI; Muromoto R; Toda J; Ichii M; Oritani K; Matsuda T
    Biochem Biophys Res Commun; 2021 Jun; 556():185-191. PubMed ID: 33845308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
    Wang LX; Wang JD; Chen JJ; Long B; Liu LL; Tu XX; Luo Y; Hu Y; Lin DJ; Lu G; Long ZJ; Liu Q
    Sci Rep; 2016 Nov; 6():35533. PubMed ID: 27824120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
    Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
    Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.